Ibrutinib Induces Rapid Down-Regulation of Inflammatory Markers and Altered Transcription of Chronic Lymphocytic Leukaemia-Related Genes in Blood and Lymph Nodes

British Journal of Haematology - United Kingdom
doi 10.1111/bjh.15516
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Wiley

Related search

Arresting the Inflammatory Drive of Chronic Lymphocytic Leukemia With Ibrutinib

Clinical Cancer Research
Cancer ResearchOncology
2016English

Comparison of Innate Immunity Changes Following Ibrutinib and Venetoclax Treatment of Relapsed Chronic Lymphocytic Leukaemia

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Lack of Adequate Pneumococcal Vaccination Response in Chronic Lymphocytic Leukaemia Patients Receiving Ibrutinib

British Journal of Haematology
Hematology
2017English

Unravelling the Suboptimal Response of TP53 -Mutated Chronic Lymphocytic Leukaemia to Ibrutinib

British Journal of Haematology
Hematology
2018English

Chronic Lymphocytic Leukaemia

Nature Reviews Disease Primers
Medicine
2017English

Ibrutinib Enhances the Efficacy of ROR1 Bispecific T Cell Engager Mediated Cytotoxicity in Chronic Lymphocytic Leukaemia

British Journal of Haematology
Hematology
2019English

Long-Term Ibrutinib Therapy Reverses CD8+ T Cell Exhaustion in B Cell Chronic Lymphocytic Leukaemia

Frontiers in Immunology
AllergyImmunology
2019English

Beyond Ibrutinib Resistance in Chronic Lymphocytic Leukemia

Cancer therapy & Oncology International Journal
2017English

Cost-Effectiveness of Ibrutinib in Patients With Relapsed or Refractory (RR) Chronic Lymphocytic Leukaemia (CLL) in England

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy